Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
0 hedge funds and large institutions have $0 invested in Alpine Immune Sciences Inc in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 178 closing their positions.
100% less funds holding
Funds holding: 180 → 0 (-180)
100% less funds holding in top 10
Funds holding in top 10: 11 → 0 (-11)
100% less capital invested
Capital invested by funds: $2.56B → $0 (-$2.56B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 178
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
-$330M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$229M |
| 3 |
BlackRock
New York
|
-$142M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$124M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$122M |
ALPN Hedge Fund Activity: Q2 2024 in Review
0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2024, worth a combined $0 — down 100% from $2.56B a quarter earlier.
Sellers outnumbered buyers: 178 funds closed out of ALPN and 0 opened new positions — a net loss of 178 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Decheng Capital, exiting entirely with an estimated $330M sold.
- 0 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2024, down from 180 in Q1 2024.
- Funds reported $0 of Alpine Immune Sciences Inc stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new Alpine Immune Sciences Inc positions in Q2 2024 and 178 closed out, a net change of -178 holders.
- The largest Alpine Immune Sciences Inc seller in Q2 2024 was Decheng Capital, an estimated $330M sold.
Based on aggregated 13F filings for Q2 2024.